Advancements of Prussian blue-based nanoplatforms in biomedical fields: Progress and perspectives

J Control Release. 2022 Oct 7:S0168-3659(22)00677-0. doi: 10.1016/j.jconrel.2022.10.007. Online ahead of print.ABSTRACTPrussian blue (PB) nanoparticles possess excellent physicochemical properties, including imaging features, robust photothermal conversion ability, catalytic activity, surface modifiability, effective drug loading, good stability, biocompatibility and biodegradability. With the advancement of nanotechnology, diverse PB-based nanoplatforms have been developed for biomedical applications. This review systematically summarized recent studies on PB-based nanoplatforms in the treatment of tumor (photothermal therapy, photodynamic therapy, chemotherapy, immunotherapy, theranostics, etc.), cardiovascular and cerebrovascular diseases (restenosis, atherosclerosis, thrombosis, ischemic stroke, etc.), bacterial infections (photothermal sterilization, biofilms disruption, etc.), and other inflammation-related diseases (liver injury, acute pancreatitis, inflammatory bowel disease, osteoarthritis, etc.). Finally, the existing challenges associated with current studies are discussed, and the future possible research and application directions for PB-based nanoplatforms are proposed, providing paradigms for subsequent development.PMID:36216173 | DOI:10.1016/j.jconrel.2022.10.007
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research